Chinese scientist "Nature" sub-published article provides new direction for new crown antibody drug research and development

Article source: Pharmaceutical Guanlan

In the past year, the development of neutralizing antibodies has become one of the main strategies for humans to fight against COVID-19.

This research comes from scientists from the Fifth Affiliated Hospital of Sun Yat-Sen University, Jinan University and Techno Microbiology.

A number of studies have shown that there is complement activation in multiple organs of severe COVID-19 patients and severe acute respiratory syndrome (SARS) patients.

The N protein of SARS-CoV-2 is a highly immunogenic protein that can trigger high titer binding antibodies in humoral immune responses.

In this work, the researchers screened and isolated a fully human antibody nCoV396 that targets the N protein of the new coronavirus based on the plasma of recovered patients with new coronaviruses who have been discharged from the hospital, and determined the antigenic table of the antibody that recognizes the N protein.

At the same time, the researchers also confirmed through experiments that the selected N protein antibody can activate the body's primary immune response to viral infections like the S protein antibody, and is superior to the S protein antibody in the secondary immune response effect.

All in all, this experiment shows that the antibody nCoV396 screened by the researchers can effectively inhibit the overactivation of complement induced by N protein, which may provide better treatment effects for patients with new coronary disease who have excessive complement activation.

Reference

[1]Kang, S.

▽ attention [drug Mingkang Germany ] micro-channel public number